Instacart vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
NASDAQ: CART grocery marketplace at $3.22B FY2024 revenue with 1,400+ retailers and $1B+ Carrot Ads business; Caper Cart AI smart cart competing with DoorDash and Walmart+ for online grocery and CPG advertising.
About
Instacart (Maplebear Inc.) is a San Francisco-based grocery technology company — listed on NASDAQ (NASDAQ: CART) following its September 2023 IPO at a $9.9 billion valuation — operating the largest US online grocery marketplace with partnerships with 1,400+ retailers and 85,000+ stores (Kroger, Costco, Albertsons, Publix, Aldi, Whole Foods), 600,000+ shoppers who fulfill same-day delivery and pickup orders, and advertising technology (Instacart Ads) that enables consumer packaged goods brands to reach shoppers at the moment of purchase intent. Instacart generated $3.22 billion in total revenue in fiscal year 2024 (+11% year-over-year) and is developing Caper Cart (AI-powered smart shopping cart technology with integrated computer vision scanning), Carrot Ads (retail media network for CPG brands), and Instacart Platform (white-label grocery e-commerce infrastructure) as its technology expansion beyond the core marketplace. Founded in 2012 by Apoorva Mehta, who famously ordered beer as the first Instacart delivery to test the service.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.